RBCC Signs Letter of Intent With Cutting-Edge Biosciences Firm

Rainbow Biosciences, a division of Rainbow Coral Corp. (OTCBB:RBCC) announced today that it signed a letter of intent to acquire or form a new joint venture with cutting-edge biotech firm n3D Biosciences, Inc. (n3D).

In collaboration with the MD Anderson Cancer Center in Houston and Rice University, n3D has developed a proprietary process that enables scientists to grow cells in a three dimensional environment. The breakthrough product uses nano particles that produce magnetic fields to lift cells from the bottom of petri dishes.

Compared with conventional cell cultures grown on flat surfaces, these 3-D cultures form tissues that more closely resemble those found in the human body. The technique has the potential to drastically reduce the cost of developing new drugs as well as eliminate the use of animals when testing the safety of manufactured chemicals.

“N3D's technique is simple, fast, and requires no special equipment,” said RBCC CEO Patrick Brown. “These are huge advantages over other technologies that have attempted to take cell culturing into the third dimension. We think n3D could be a perfect fit with RBCC, and we look forward to signing a definitive agreement soon.”

For more information on Rainbow BioSciences, RBCC's biotechnology division, please visit www.rainbowbiosciences.com/investors.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc. (NASDAQ: CTIC), Abbott Laboratories (NYSE:ABT - News) Affymax, Inc. (NASDAQ:AFFY - News), and Celgene Corp. (NASDAQ:CELG - News).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a division of Rainbow Coral Corp. (OTCBB:RBCC.ob - News). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.